MX368214B - Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4). - Google Patents

Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).

Info

Publication number
MX368214B
MX368214B MX2017010348A MX2017010348A MX368214B MX 368214 B MX368214 B MX 368214B MX 2017010348 A MX2017010348 A MX 2017010348A MX 2017010348 A MX2017010348 A MX 2017010348A MX 368214 B MX368214 B MX 368214B
Authority
MX
Mexico
Prior art keywords
compounds
receptor agonists
amide compounds
relates
receptor
Prior art date
Application number
MX2017010348A
Other languages
English (en)
Other versions
MX2017010348A (es
Inventor
Ramkumar Subramanian
Ramakrishna Nirogi
Gopinadh Bhyrapuneni
Abdul Rasheed Mohammed
Anil Karbhari Shinde
Sangram Keshari Saraf
Pradeep Jayarajan
Bogaraju Narsimha
Jasti Venkateswarlu
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2017010348A publication Critical patent/MX2017010348A/es
Publication of MX368214B publication Critical patent/MX368214B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se relaciona con compuestos de la fórmula (I), incluyendo sus estereoisómeros y sales farmacéuticamente aceptables. Esta invención también se relaciona con métodos para hacer tales compuestos y con las composiciones farmacéuticas que comprenden tales compuestos. Los compuestos de esta invención son útiles en el tratamiento de varios trastornos que están relacionados con el receptor de la 5-hidroxitriptamina 4 (5-HT4). (ver Fórmula).
MX2017010348A 2015-02-13 2016-01-07 Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4). MX368214B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN709CH2015 2015-02-13
PCT/IN2016/000008 WO2016128990A1 (en) 2015-02-13 2016-01-07 Amide compounds as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
MX2017010348A MX2017010348A (es) 2018-06-07
MX368214B true MX368214B (es) 2019-09-24

Family

ID=55588327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010348A MX368214B (es) 2015-02-13 2016-01-07 Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).

Country Status (29)

Country Link
US (1) US9957257B2 (es)
EP (1) EP3265459B1 (es)
JP (1) JP6487564B2 (es)
KR (1) KR101966576B1 (es)
CN (1) CN107406434B (es)
AU (1) AU2016217461B2 (es)
BR (1) BR112017017275A2 (es)
CA (1) CA2975973C (es)
CY (1) CY1121898T1 (es)
DK (1) DK3265459T3 (es)
EA (1) EA034618B1 (es)
ES (1) ES2734734T3 (es)
HR (1) HRP20191179T1 (es)
HU (1) HUE045667T2 (es)
IL (1) IL253848B (es)
LT (1) LT3265459T (es)
MA (1) MA41633B1 (es)
MD (1) MD3265459T2 (es)
ME (1) ME03430B (es)
MX (1) MX368214B (es)
NZ (1) NZ734400A (es)
PL (1) PL3265459T3 (es)
PT (1) PT3265459T (es)
RS (1) RS59066B1 (es)
SG (1) SG11201706501VA (es)
SI (1) SI3265459T1 (es)
TR (1) TR201909997T4 (es)
WO (1) WO2016128990A1 (es)
ZA (1) ZA201705292B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187451B2 (en) 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN110818661B (zh) * 2019-12-02 2021-08-06 上海再启生物技术有限公司 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416813A (pt) 2003-11-24 2007-03-06 Pfizer compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
CA2598516C (en) 2005-02-25 2010-05-11 Pfizer Inc. Benzisoxazole derivatives
EP1910340B1 (en) 2005-07-22 2009-11-18 Pfizer, Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
AR056729A1 (es) * 2005-10-28 2007-10-17 Glaxo Group Ltd Compuesto de benzofurano carboxamida, composicion farmaceutica que lo comprende su uso para preparar un medicamento y procesos para su preparcion
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
CA2789663C (en) 2010-02-12 2018-10-02 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
MX337721B (es) 2011-09-19 2016-03-16 Suven Life Sciences Ltd Compuestos de heteroarilo como ligandos del receptor 5-ht4.
ES2674993T3 (es) * 2013-03-20 2018-07-05 Suven Life Sciences Limited Derivados de 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-HT4
EP3099675B1 (en) 2013-12-16 2018-02-14 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
SI3265459T1 (sl) 2019-09-30
RS59066B1 (sr) 2019-09-30
MD3265459T2 (ro) 2019-09-30
CN107406434A (zh) 2017-11-28
MA41633B1 (fr) 2019-07-31
BR112017017275A2 (pt) 2018-04-17
EA034618B1 (ru) 2020-02-27
ME03430B (me) 2020-01-20
TR201909997T4 (tr) 2019-07-22
HUE045667T2 (hu) 2020-01-28
AU2016217461A1 (en) 2017-09-14
EP3265459A1 (en) 2018-01-10
IL253848B (en) 2018-01-31
MA41633A (fr) 2019-05-15
MX2017010348A (es) 2018-06-07
SG11201706501VA (en) 2017-09-28
CY1121898T1 (el) 2020-10-14
PL3265459T3 (pl) 2019-09-30
ES2734734T3 (es) 2019-12-11
CN107406434B (zh) 2020-09-11
PT3265459T (pt) 2019-07-17
CA2975973C (en) 2019-07-16
KR20170117167A (ko) 2017-10-20
AU2016217461B2 (en) 2018-07-05
CA2975973A1 (en) 2016-08-18
IL253848A0 (en) 2017-09-28
WO2016128990A1 (en) 2016-08-18
HRP20191179T1 (hr) 2019-10-04
ZA201705292B (en) 2019-06-26
EA201791829A1 (ru) 2018-05-31
JP6487564B2 (ja) 2019-03-20
JP2018509396A (ja) 2018-04-05
DK3265459T3 (da) 2019-07-15
US9957257B2 (en) 2018-05-01
KR101966576B1 (ko) 2019-04-05
EP3265459B1 (en) 2019-05-15
LT3265459T (lt) 2019-08-26
NZ734400A (en) 2018-03-23
US20180051011A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
SA518391624B1 (ar) Ror- منظمات جاما
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
PH12016501440A1 (en) Novel heterocyclic compounds
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2020010674A (es) Agonistas del receptor muscarinico.
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
PH12017500821A1 (en) Morpholine and 1, 4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
PH12017501736A1 (en) Indole derivatives
PH12017501134A1 (en) Fumagillol derivatives
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
WO2014147636A8 (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.

Legal Events

Date Code Title Description
FG Grant or registration